VantAI, a company focused on generative AI-enabled drug discovery, and Bristol Myers Squibb, a leading pharmaceutical company, have entered into a strategic ...
VantAI
(1)
Corporate office in New York
Address: 116 E 16th St, New York, NY 10003
Hours: Closed ⋅ Opens 9 AM Mon
VantAI pairs bleeding-edge machine learning techniques with deep systems biology expertise to build computational models that uncover hidden relationships ...
VantAI Enters Collaboration With Bristol Myers ... - Business Wire
www.businesswire.com › news › home
Feb 13, 2024 · The collaboration will focus on leveraging VantAI's generative AI platform to design molecular glues as small molecule therapeutics. These ...
People also ask
What is Gen AI in drug discovery?
What is wand AI?
Dec 7, 2020 · Roivant Sciences announced its targeted protein degradation platform, with its first pipeline candidate expected to enter the clinic in 2021.
People also search for
Really well-written, intriguing, and not overly hyped perspective on the promises and needs for AI in Biology. Emphasis on high-throughput, low-cost “black-box” ...
VantAI builds computational models that identify hidden links between molecules, targets, and diseases by combining the machine learning approach with deep ...
Feb 14, 2024 · BMS signs $674m GenAI drug discovery deal with VantAI. The partnership will focus on designing molecular glues for unspecified therapeutic ...
Feb 13, 2024 · BMS is offering Roivant's VantAI up to $674 million in a new partnership aimed at designing molecular glues as small-molecule therapeutics.